File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children

TitleAutologous hematopoietic stem cell transplantation for high-risk brain tumors in children
Authors
KeywordsAutologous hematopoietic stem cell transplantation
Brain tumor
Children
Relapse
Issue Date2008
PublisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-594X
Citation
Journal Of Neuro-Oncology, 2008, v. 86 n. 3, p. 337-347 How to Cite?
AbstractAutologous hematopoietic stem cell transplant (AHSCT) has been advocated as a form of salvage therapy for children with high-risk or relapsed brain tumors but only limited data are available currently. We report the outcomes of pediatric brain tumors treated with AHSCT in a quaternary referral center in Hong Kong over 10 years (June 1996-May 2006). Thirteen patients with medulloblastoma (n = 9), cerebral primitive neuroectodermal tumor (n = 1), ependymoma (n = 1), germ cell tumor (n = 1) and cerebellar rhabdoid (n = 1) were transplanted because of tumor residual (n = 1) or recurrence (n = 12). Uniform upfront treatment protocols were adopted according to specific tumor types. Prior to AHSCT, 8 patients (61.5%) achieved complete remission and 5 (38.5%) were in partial remission. Conditioning employed thiotepa 300 mg/m2, etoposide 250 mg/m2 and carboplatin 500 mg/m2 daily for 3 days. Toxicity included mucositis and neutropenic fever in all patients, grade 4 hepatic toxicity in 4 patients (including hepatic veno-occlusive disease in 2 patients) and grade 4 renal toxicity in 1 patient. The 5-year event-free survival was 53.9%. Five patients died of disease recurrence or progression 8-21 months after transplant with a median disease-free period of 8 months post-transplant. One died of transplant-related complications in the early post-transplant period. Seven survived for a median of 5.4 years (maximum follow-up of 9.8 years), with six having Lansky-Karnofsky performance score above 80. All survivors had complete remission before transplant though 2 had leptomeningeal spread. We conclude that AHSCT can achieve long-term survival in children with recurrent brain tumor. However, those with macroscopic residual tumor before transplant cannot be salvaged. © Springer Science+Business Media, LLC. 2007.
Persistent Identifierhttp://hdl.handle.net/10722/79946
ISSN
2015 Impact Factor: 2.754
2015 SCImago Journal Rankings: 1.274
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorCheuk, DKLen_HK
dc.contributor.authorLee, TLen_HK
dc.contributor.authorChiang, AKSen_HK
dc.contributor.authorHa, SYen_HK
dc.contributor.authorChan, GCFen_HK
dc.date.accessioned2010-09-06T08:00:36Z-
dc.date.available2010-09-06T08:00:36Z-
dc.date.issued2008en_HK
dc.identifier.citationJournal Of Neuro-Oncology, 2008, v. 86 n. 3, p. 337-347en_HK
dc.identifier.issn0167-594Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/79946-
dc.description.abstractAutologous hematopoietic stem cell transplant (AHSCT) has been advocated as a form of salvage therapy for children with high-risk or relapsed brain tumors but only limited data are available currently. We report the outcomes of pediatric brain tumors treated with AHSCT in a quaternary referral center in Hong Kong over 10 years (June 1996-May 2006). Thirteen patients with medulloblastoma (n = 9), cerebral primitive neuroectodermal tumor (n = 1), ependymoma (n = 1), germ cell tumor (n = 1) and cerebellar rhabdoid (n = 1) were transplanted because of tumor residual (n = 1) or recurrence (n = 12). Uniform upfront treatment protocols were adopted according to specific tumor types. Prior to AHSCT, 8 patients (61.5%) achieved complete remission and 5 (38.5%) were in partial remission. Conditioning employed thiotepa 300 mg/m2, etoposide 250 mg/m2 and carboplatin 500 mg/m2 daily for 3 days. Toxicity included mucositis and neutropenic fever in all patients, grade 4 hepatic toxicity in 4 patients (including hepatic veno-occlusive disease in 2 patients) and grade 4 renal toxicity in 1 patient. The 5-year event-free survival was 53.9%. Five patients died of disease recurrence or progression 8-21 months after transplant with a median disease-free period of 8 months post-transplant. One died of transplant-related complications in the early post-transplant period. Seven survived for a median of 5.4 years (maximum follow-up of 9.8 years), with six having Lansky-Karnofsky performance score above 80. All survivors had complete remission before transplant though 2 had leptomeningeal spread. We conclude that AHSCT can achieve long-term survival in children with recurrent brain tumor. However, those with macroscopic residual tumor before transplant cannot be salvaged. © Springer Science+Business Media, LLC. 2007.en_HK
dc.languageengen_HK
dc.publisherSpringer New York LLC. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-594Xen_HK
dc.relation.ispartofJournal of Neuro-Oncologyen_HK
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectAutologous hematopoietic stem cell transplantationen_HK
dc.subjectBrain tumoren_HK
dc.subjectChildrenen_HK
dc.subjectRelapseen_HK
dc.titleAutologous hematopoietic stem cell transplantation for high-risk brain tumors in childrenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1545-5009&volume=&spage=&epage=&date=2006&atitle=Autologous+hematopoietic+stem+cell+transplantation+for+high+risk+brain+tumors+in+children.+en_HK
dc.identifier.emailChiang, AKS:chiangak@hkucc.hku.hken_HK
dc.identifier.emailChan, GCF:gcfchan@hkucc.hku.hken_HK
dc.identifier.authorityChiang, AKS=rp00403en_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s11060-007-9478-0en_HK
dc.identifier.pmid17906911-
dc.identifier.scopuseid_2-s2.0-38049048723en_HK
dc.identifier.hkuros145791en_HK
dc.identifier.hkuros142312-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-38049048723&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume86en_HK
dc.identifier.issue3en_HK
dc.identifier.spage337en_HK
dc.identifier.epage347en_HK
dc.identifier.isiWOS:000252157400011-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridCheuk, DKL=8705936100en_HK
dc.identifier.scopusauthoridLee, TL=8508917400en_HK
dc.identifier.scopusauthoridChiang, AKS=7101623534en_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats